
Sunday, December 30, 2018 1:44:31 PM
This is the entire pipeline: B & K.
If you sell everything for pennies on the dollar, when Leo's lowest current offer is indicating that B-OM is worth $150M/yr, then I'm not sure this would be even part of his consideration set.
Keep in mind that P53 modulation is sort of the 'holy grail' for cancer treatments. Leo's view of K is likely vastly different than what you're articulating here.
I feel based on the info they've provided to-date and the B-OM market, that B-OM alone should be worth a sum greater than $1B in a license-structured deal.
IMHO.
2) $200-600 million buyout of B and K
Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement • COEP • Apr 25, 2025 8:33 AM
UAV Corp. Successfully Completes Inflation Test of DART SA-70 Airship, Paving Way for Flight Readiness • UMAV • Apr 24, 2025 8:30 AM
InnerScope Hearing Technologies (OTC: INND) Announces the Grand Opening of OTCHealthMart.com • INND • Apr 24, 2025 8:00 AM
Opus Holdings Unveils Powerhouse Leadership Team to Drive Aggressive Growth and Transform Market Trajectory • CATV • Apr 22, 2025 8:30 AM
Glidelogic Corp. (OTCQB: GDLG) Highlights Independent SOTA Evaluation of ResearchMind Platform • GDLG • Apr 22, 2025 6:54 AM
UAV Corp to Launch Inflation Test of SA-70 Airship This Week-A Gateway to High-Value Government and Defense Contracts • UMAV • Apr 21, 2025 1:30 PM